Hims & Hers Health Inc. Stock News

Shares of Hims & Hers Health (HIMS -24.30%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m.

The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.

The FDA announced on Friday that the shortage of semaglutide injection products like Novo Nordisk's Ozempic and Wegovy has been resolved. The FDA said Friday that it will start taking action against compounders for violations in the next 60 to 90 days.

“The Next NVIDIA” Could Change Your Life NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.

Hims & Hers Health Inc (NYSE:HIMS) stock has had a roller coaster week.

HIMS stock fell after the FDA said the shortages in Novo Nordisk's weight-loss drug has been resolved. The post Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage appeared first on Investor's Business Daily.

Shares of Hims & Hers Health plunged a massive 25% on Friday to hit an intraday low of around $49.01. The massive crash came after the US Food and Drug Administration (FDA) announced the end of the shortage of Novo Nordisk's weight-loss drugs.

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc., the leading health and wellness platform, today announced an acquisition that will further verticalize the company's long-term ability to deliver personalized medications. The company has acquired a US-based peptide facility based in California. The acquisition will enable the company to strengthen the long-term durability of its domesti...